Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

NCT07829185 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT07829185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07829185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
University of Oklahoma
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac)